The current studies indicate that a PD-1/PD-L1 blockade in combination with surgery, chemotherapy, radiotherapy, molecular targeted therapy, or other immunotherapies could modulate the immunoediting process, TME and the immune response in pancreatic cancer, which have been or will be validated in the latest clinical trials. This evidence concerns the gene PDCD1 and pancreatic neoplasm.